Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19612877 | 0.90 | SCN8A (1.00) | SCN8ASCN1A | |
| SCHEMBL19612878 | 0.90 | SCN8A (1.00) | SCN8ASCN1A | |
| SCHEMBL19612902 | 0.89 | SCN8A (1.00) | SCN8ASCN1A | |
| SCHEMBL19612903 | 0.89 | SCN8A (1.00) | SCN8ASCN1A | |
| SCHEMBL19613034 | 0.87 | SCN8A (1.00) | SCN8ASCN1A | |
| Zandatrigine SCHEMBL19612884 | 0.87 | SCN8A (1.00) | SCN8ASCN1A | |
| Zandatrigine SCHEMBL19612883 | 0.87 | SCN8A (1.00) | SCN8ASCN1A | |
| Zandatrigine SCHEMBL19613237 | 0.87 | SCN8A (1.00) | SCN8ASCN1A | |
| SCHEMBL19613446 | 0.87 | SCN8A (1.00) | SCN8ASCN1A | |
| SCHEMBL19613445 | 0.87 | SCN8A (1.00) | SCN8ASCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230404913-A1 | PHARMACEUTICAL FORMULATIONS FOR TREATING DISEASES ASSOCIATED WITH VOLTAGE-GATED SODIUM CHANNELS | XENON PHARMACEUTICALS INC. (CA) | 2023-12-21 | — | — | US | disclosed |
| EP-4228653-A1 | PHARMACEUTICAL FORMULATIONS FOR TREATING DISEASES ASSOCIATED WITH VOLTAGE-GATED SODIUM CHANNELS | Xenon Pharmaceuticals Inc. (CA) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022077094-A1 | PHARMACEUTICAL FORMULATIONS FOR TREATING DISEASES ASSOCIATED WITH VOLTAGE-GATED SODIUM CHANNELS | XENON PHARMACEUTICALS INC. (CA) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230404913-A1 | PHARMACEUTICAL FORMULATIONS FOR TREATING DISEASES ASSOCIATED WITH VOLTAGE-GATED SODIUM CHANNELS | SCN4A, SCN5A, KCNJ4 | SCN8A 6/4885SCN1A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.